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We analyzed 43 CTX-M-15–producing Escherichia coli 
isolates and 6 plasmids encoding the blaCTX-M-15 gene from 
Canada, India, Kuwait, France, Switzerland, Portugal, and 
Spain. Most isolates belonged to phylogroups B2 (50%) and 
D (25%). An EC-B2 strain of clonal complex sequence type 
(ST) 131 was detected in all countries; other B2 isolates 
corresponded to ST28, ST405, ST354, and ST695 from 
speciﬁ   c areas. EC-D strains were clonally unrelated but 
isolates from 3 countries belonged to ST405. All CTX-M-15 
plasmids corresponded to IncFII group with overrepresen-
tation of 3 HpaI-digested plasmid DNA proﬁ  les (A, B and 
C; 85–120kb, similarity >70%). Plasmid A was detected in 
EC-B2 strains (ST131, ST354, or ST405), plasmid C was 
detected in B2 and D strains, and plasmid B was conﬁ  ned to 
worldwide-disseminated ST131. Most plasmids contained 
blaOXA-1, aac(6′)-Ib-cr, and blaTEM-1. Worldwide dissemination 
of CTX-M-15 seems to be determined by clonal complexes 
ST131 and ST405 and multidrug-resistant IncFII plasmids.
P
lasmid-mediated CTX-M type expanded-spectrum β-
lactamases (ESBLs), which have been extensively re-
ported for the past 10 years, are detected mostly in com-
munity-acquired pathogens and are associated mainly with 
Escherichia coli. These β-lactamases compromise the ef-
ﬁ  cacy of all β-lactams, except carbapenems and cephamy-
cins, and are associated with many non–β-lactam resistance 
markers because of their locations on plasmids. Therefore, 
they may constitute a real threat for treating community-
acquired E. coli–mediated urinary tract infections (1,2).
Different variants of CTX-M ESBLs are grouped in 5 
clusters, although their distribution varies greatly depend-
ing on the geographic area (www.lahey.org/studies/webt.
htm). CTX-M-15, which was ﬁ  rst detected in isolates from 
India in 2001 (3), is now recognized as the most widely 
distributed CTX-M enzyme. It is derived from CTX-M-
3 by 1 amino acid substitution at position 240 (Asp-240 
→ Gly), which apparently confers an increased catalytic 
activity to ceftazidime (4). Clonal outbreaks of CTX-M-
15–producing Enterobacteriaceae have been reported in 
France, Italy, Spain, Portugal, Austria, Norway, the United 
Kingdom, Tunisia, South Korea, and Canada, and E. coli is 
the most frequently involved species. Within E. coli, CTX-
M-15–producing strains of the B2 phylogenetic group are 
commonly found and frequently harbor multidrug resis-
tance and virulence determinants (5–18).
Plasmids encoding blaCTX-M-15 have been isolated from 
clinical isolates in France, Spain, Portugal, the United 
Kingdom, Canada, India, Pakistan, South Korea, Tai-
wan, the United Arabic Emirates, and Honduras (5–8,
10,11,15,19,20).  Plasmid characterization, which has only 
been accomplished for those plasmids from Canada, France, 
Spain, and the United Kingdom, classiﬁ  ed most of them as 
members of incompatibility group FII (5,7,8,17,19).
Lack of detailed studies on isolates expressing particu-
lar CTX-Ms from different geographic areas has precluded 
identiﬁ  cation of factors involved in recent and worldwide 
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spread of speciﬁ  c CTX-M variants. In this article, through 
analysis of the population biology of CTX-M-15–produc-
ing isolates from 7 countries and characterization of their 
genetic elements, we provide a comprehensive picture of 
elements involved in international spread of a particularly 
widespread mechanism of antimicrobial drug resistance.
Materials and Methods
Bacterial Strains, Production of ESBL, 
and Susceptibility Testing
We studied 43 CTX-M-15–producing E. coli clinical 
isolates from France (n = 17), Kuwait (n = 9), Switzerland 
(n = 7), Canada (n = 4), Portugal (n = 3) and Spain (n = 
3), and 6 CTX-M-15 plasmids from India (3), all obtained 
from 2000 through 2006. These strains and plasmids were 
considered representative of these areas because they 
either caused outbreaks or were the ﬁ  rst isolates recov-
ered in those countries (3,11,16,19,21–23). Samples were 
isolated from urine (n = 33/43, 77%), wounds (n = 4/43, 
9.%), respiratory tract infections (n = 3/43, 7%) and other 
sites (1 from feces, 1 from an intravenous catheter, and 
1 from blood) in hospitalized patients. ESBL production 
was conﬁ  rmed by a standard double-disk synergy test, 
and bla genes were characterized by PCR and additional 
sequencing as described (19). Susceptibility patterns to 13 
non–β-lactam antimicrobial drugs were determined by the 
standard disk diffusion method following published stan-
dards (24). Strains with intermediate susceptibility were 
considered resistant.
Clonal Relationships
Clonal relationships were established by pulsed-ﬁ  eld 
gel electrophoresis (PFGE) of XbaI-digested genomic 
DNA (New England Biolabs, Ipswich, MA, USA) as de-
scribed (25). Assignment of E. coli phylogenetic groups 
was conducted by using a multiplex PCR assay described 
by Clermont et al. (26). All E. coli isolates belonging to 
phylogroups B2 and D were characterized by multilocus 
sequence typing (MLST) using the standard 7 housekeep-
ing loci (www.mlst.net). All fumC sequences from E. coli 
isolates belonging to phylogroup D were analyzed for a 
C288T single nucleotide polymorphism. This polymor-
phism is speciﬁ  c for a globally disseminated E. coli strain 
arbitrarily designated as E. coli clonal group A (CgA) that 
is associated with community-acquired urinary tract infec-
tions (27,28).
Transferability and Location of blaCTX-M-15
Transferability was tested by broth and ﬁ  lter mating 
assays using E. coli K12 strain BM21R (resistant to nali-
dixic acid and rifampin, positive for lactose fermentation, 
and free of plasmids) as recipient at a 1:2 donor: recipient 
ratio. Transconjugants were selected on Luria-Bertani agar 
plates containing cefotaxime (1 mg/L) and rifampin (100 
mg/L) and incubated at 37°C for 24–48 h. Transforma-
tion was performed for a subset of isolates by using con-
ditions reported (3). Chromosomal or plasmid location of 
blaCTX-M-15 genes was assessed by hybridization of I-CeuI–
digested genomic DNA with blaCTX-M-15 and 16S rDNA 
probes and electrophoresis (5–25 s for 23 h and 60–120 s 
for 10 h at 14°C and 6 V/cm2) (25). Transfer and hybrid-
ization were performed by using standard procedures. La-
beling and detection were conducted by using enhanced 
chemiluminescence (Amersham Life Sciences, Uppsala, 
Sweden) following manufacturer’s instructions.
Plasmid Characterization
Plasmid DNA was obtained by using different midi-
prep plasmid puriﬁ   cation kits (QIAGEN, Hilden, Ger-
many, and Marlingen Biosciences, Ijamsville, MD, USA). 
Plasmids were classiﬁ  ed according to their incompatibility 
group by a PCR-based replicon-typing scheme (29). De-
termination of plasmid size and conﬁ  rmation of replicon 
content was established for transconjugants (or wild-type 
strains in the absence of transfer) by hybridization of S1 
nuclease–digested genomic DNA with probes speciﬁ  c for 
blaCTX-M-15 and for different F replicons (FII, FIA, FIB), 
which were obtained by PCR as described (19). Relation-
ships among plasmids were determined by comparison of 
EcoRI and HpaI digested DNA patterns and comparison 
of repFII sequences. Genescan software (Applied Bio-
systems, Foster City, CA, USA) was used for collection 
of gel images. Data of a subset of representative patterns 
were exported into Fingerprinting II Informatix version 3.0 
software (Bio-Rad Laboratories, Hercules, CA, USA) for 
further interpretation. Cluster analysis was conducted by 
using the unweighted pair group method with arithmetic 
averages (optimization 0.5%, tolerance 1.00%).
Presence of genes previously associated with plasmids 
encoding CTX-M-15 as blaOXA-1, blaTEM-1, and aac(6′)-Ib-cr 
was screened by PCR by using primers blaOXA-1 (oxa1 FW: 
5′-TTT TCT GTT GTT TGG GTT TT-3′ and oxa1 RV: 5′-
TTT CTT GGC TTT TAT GCT TG-3′), blaTEM-1 (TEM-F: 
5′-ATG AGT ATT CAA CAT TTC CG-3′ and TEM-R: 
5′-CTG ACA GTT ACC AAT GCT TA-3′), and aac(6′)-
Ib-cr (aac-cr-F: 5′-TTG CGA TGC TCT ATG AGT GG-3′ 
and aac-cr-R: 5′-GCG TGT TCG CTC GAA TGC C-3′) 
(11,19,30). Additional sequencing was necessary to iden-
tify the corresponding genes.
Results
Epidemiologic Background
Most CTX-M-15–producing E. coli isolates belonged 
to phylogroups B2 (50%) and D (25%), which are known 
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to be associated with the hospital setting and extraintesti-
nal pathogenic E. coli. Phylogroups A (18%) and B1 (7%), 
which are associated with animal or human commensal 
strains, were less frequently represented. All isolates of 
phylogroups B2, A, and D corresponded to subgroups B23, 
A1, and D1, respectively, which are the most common ones 
within each phylogenetic group (31). The 43 clinical iso-
lates were classiﬁ  ed into 32 PFGE types (B23, 13; D1, 10; 
A1, 6; and B1, 3). Among B23 strains, 10 PFGE types (18 
isolates from France, Canada, Spain, Portugal, Kuwait, and 
Switzerland) were possibly related according to criteria of 
Tenover et al. (32) (difference <6 bands, >80% similarity) 
and were assigned to the sequence type (ST) ST131. The 4 
unrelated B2 strains were classiﬁ  ed within ST695 (1 from 
France), ST28 (1 from Switzerland), ST354 (1 from Por-
tugal and Spain) and ST405 (1 from Portugal). All isolates 
of phylogroup D1 were clonally unrelated by PFGE (dif-
ference >6 bands), although MLST studies indicated that 
4 PFGE types (5 isolates) from Kuwait, Switzerland, and 
Spain corresponded to ST405. The fumC sequences of the 
remaining 6 E. coli D strains were highly diverse (alleles 
4, 13, 26, 88, and 132). None of the strains had the C288T 
single nucleotide polymorphism speciﬁ  c for E. coli strain 
CgA (28). All 3 B1 isolates were found in France. Among 
B2 E. coli isolates, all but 4 were isolated from urine and 
all but 2 belonged to ST131. These strains correspond to 
2 isolates recovered from wounds and identiﬁ  ed as ST28 
and ST354 and 2 ST131 isolates from respiratory and fecal 
samples, respectively.
CTX-M-15 clinical strains were considered resistant 
to different antimicrobial drugs: amoxicillin-clavulanate 
(98%), tobramycin (89%), kanamycin (87%), tetracy-
cline (84%), gentamicin (82%), nalidixic acid (74%), 
streptomycin (68%), sulfonamides (61%), ciproﬂ  oxacin 
(61%), trimethoprim (58%), chloramphenicol (21%), ni-
trofurantoin (12%), and amikacin (11%). All CTX-M-15 
transconjugants expressed resistance to aminoglycosides, 
tetracycline, or trimethoprim. All but 2 strains contained 
blaOXA-1 and aac(6′)-Ib-cr; 1 contained only aac(6′)-Ib-cr, 
and 1 contained blaOXA-1 and aacA4, which confers reduced 
susceptibility to amikacin and kanamycin.
Location and Transferability of blaCTX-M-15
The blaCTX-M-15 gene was located on plasmids in all 
but 6 strains and was positively transferred by conjugation 
or transformation in 37% of the strains tested. In 8 clini-
cal isolates corresponding to 7 PFGE types, the probe for 
blaCTX-M-15 hybridized in chromosomal bands (2 belong-
ing to B23 ST131, 2 to D1, 1 to D1 ST405, and 1 to A1). In 
2 other strains, the blaCTX-M-15 probe hybridized both with 
plasmid and chromosomal bands (1 strain from D ST405 
and 1 from phylogroup B1).
Plasmids Encoding CTX-M-15
Plasmids positive for the blaCTX-M-15 gene showed vari-
able sizes (85–160 kb), belonged to the narrow host range 
incompatibility group IncF, and had replicon FII alone or 
in association with the FIA or FIB replicons (online Appen-
dix Table, available from www.cdc.gov/EID/content/14/2/
195-appT.htm). Many restriction fragment length polymor-
phism (RFLP) patterns were observed, with overrepresen-
tation of 3 proﬁ  les corresponding to 3 plasmids arbitrarily 
designated as plasmid A (85 kb), plasmid B (120 kb), and 
plasmid C (85 kb). Plasmid A, which was isolated from 
B2 E. coli strains from 4 countries (India, France, Portu-
gal, and Spain), was associated with different STs (ST131, 
ST354, or ST405). Plasmid C was also detected in clonally 
unrelated E. coli of phylogroups B2 and D from Switzer-
land, Canada and France. Plasmid B, which was only as-
sociated with E. coli ST131, was widely disseminated in 
all countries studied. Sequence analysis of the replicons 
showed 4 repFII types: repFII(1), which was identical to 
that of plasmids R100, NR1, or pC15–1a, and was the most 
represented and identiﬁ  ed in 23 plasmids; repFII(2), which 
had 99%–100% homology with plasmid pRSB107 (Gen-
Bank accession no. AJ851089), was identiﬁ  ed in 6 plas-
mids; and repFII(3) and repFII(4), which were detected in 2 
and 7 plasmids, respectively, and showed >93% homology 
with repFII(1). All repFIA and repFIB sequences were 99% 
and 100% homologous, respectively, with that of pRSB107 
(GenBank accession no. AJ851089).
Computer analysis of representative RFLP patterns 
and repFII sequences grouped CTX-M-15 plasmids within 
3 major clusters with similarity >70%. Cluster I comprises 
most plasmids, including plasmids A and B, most contain-
ing repFII(1) and showing variable replicon content. Cluster 
II comprised only plasmid C derivatives showing slightly 
different repFII sequences, and cluster III included 2 plas-
mids carrying repFII(2), FIA, and FIB replicons (Figure).
In the 8 strains with chromosomal location of blaCTX-M-15, 
repFII plasmids were identiﬁ  ed but these plasmids were 
negative for the blaCTX-M-15 gene. Several strains that were 
also positive for additional plasmids and negative for the 
blaCTX-M-15 gene were assigned to different incompatibility 
groups or were untypeable by the PCR-based replicon typ-
ing scheme used.
Discussion
Our study indicates that current worldwide spread 
of the blaCTX-M-15 gene is driven mainly by 2 epidemic E. 
coli strains belonging to phylogroups B2 (ST131) and D 
(ST405) and by its location on IncF plasmids harboring mul-
tiple antimicrobial drug–resistance determinants, including 
the recently described aac(6′)-Ib-cr gene. The presence of 
blaCTX-M-15 has previously been associated with E. coli strains 
of phylogroups B2 and D, and in some instances, with 
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speciﬁ  c PFGE types (9–12,16). We detected an emerging 
and globally disseminated CTX-M-15 phylogroup B2 E. 
coli strain corresponding to the ST131 that was responsible 
for clonal outbreaks in Canada, France, Spain, and Portu-
gal (11,14,16,23). Other CTX-M-15 B2 strains belong to 
clonal complexes ST695, ST405, ST354, or ST28, which 
have previously been detected in different geographic ar-
eas among isolates that do not express CTX-M-15 (online 
Appendix Figure, available from www.cdc.gov/EID/con-
tent/14/2/195-appG.htm). 
Globally disseminated E. coli strains associated with 
acute, uncomplicated, community-acquired cystitis and 
pyelonephritis, designated in community patients as clone 
CgA (ST69), have only been occasionally associated with 
CTX-M-15 production in Canada (16,27,28). Although 
the isolates in our study do not belong to clone CgA, they 
were isolated mainly from urine samples, and an associa-
tion of ST131 E. coli isolates with urinary tract infections 
might be inferred. Although most CTX-M-15 isolates 
studied were recovered from hospitalized patients, these 
microorganisms are now widely spread in the community 
setting, including long-term care facilities in the coun-
tries from which isolates included in this study originated 
(2,5,14,33). Our study has increased knowledge of the 
number of epidemic E. coli clonal complexes causing uri-
nary tract infections.
All plasmids carrying blaCTX-M-15 included in this study 
corresponded to incompatibility group F, and all had the FII 
replicon, which was assorted mainly in multireplicon plas-
mids with additional replicons of the FIA and FIB types. 
Association of the blaCTX-M-15 gene with IncFII replicons 
has been described in studies conducted in Canada, France, 
Spain, and the United Kingdom (5,7,8,17,19). Although 
we observed intercontinental dissemination of 3 major 
IncFII plasmid scaffolds (A, B, and C) carrying blaCTX-M-15, 
similarity >70% among all variants studied and presence of 
genes also found in pC15–1a, a CTX-M-15 plasmid (Gen-
Bank accession no. AY458016) that has a 28.4-kb mul-
tidrug resistance region containing blaTEM-1, blaOXA-1, the 
aac(6′)-Ib-cr gene (aminoglycoside 6′-N-acetyltransferase 
type Ib-cr variant responsible for reduced susceptibility to 
both aminoglycosides and certain ﬂ  uoroquinolones), and 
genetic determinants coding for resistance to tetracycline 
and aminoglycosides (5,30), suggest a common origin or 
a common particular plasmid scaffold involved in the dis-
semination of CTX-M-15. 
Because IncF plasmids are a heterogeneous and large-
ly diffused family of plasmids in E. coli, they could ac-
quire the blaCTX-M-15 gene. IncF plasmids negative for the 
blaCTX-M-15 gene in strains with this gene at a chromosomal 
location also suggest dynamic horizontal exchanges be-
tween the chromosome and resident plasmids. Extensive 
recombination events among IncF plasmids are frequent 
and may have contributed to their apparent high diversity 
(variable rep content, plasmid size, transferability, anti-
microbial drug–resistance genes), driving their evolution 
and enabling them to persist in diverse E. coli populations 
(34,35). Such recombination events among plasmids of the 
same incompatibility group within the same cell occur fre-
quently (34,35). This hypothesis is supported by the results 
of Lavollay et al. (17), who described mosaicism in a CTX-
M-15 plasmid isolated in France that contained genes from 
2 different IncFII plasmids, pC15–1a and pRSB107 (from 
IncFII plasmids ﬁ  rst isolated from persons in Canada and 
activated sludge bacteria from a wastewater treatment plant 
in Germany, respectively) (5,36).
Spread and maintenance of conjugative plasmids 
across bacterial populations have been intensively stud-
ied from a theoretical point of view, but data from natu-
ral populations are scarce (34,37,38). Recovery of related 
plasmids from clonally unrelated B2 strains might reﬂ  ect 
efﬁ  cient transfer of these elements among different B2 E. 
coli populations. Sharing the same environment, successive 
immigrant B2 strains might sweep through the population, 
enabling plasmid hitchhiking at a high frequency in each 
selective sweep. However, we lack detailed information 
on the speciﬁ  city and stability of different plasmid groups 
in speciﬁ  c hosts. An evolutionary convergent relationship 
among B2 genetic background and IncFII plasmids can-
not be ruled out and should be studied because it might 
explain successful dissemination of CTX-M-15 plasmids 
within this E. coli lineage. In addition, our study is one of 
the few that have identiﬁ  ed blaESBL genes in the chromo-
some, which might respond either to plasmid integration or 
transposition driven by ISEcp1 located upstream from the 
blaCTX-M-15 gene (25,39,40).
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Figure. Computer analysis of a subset of representative HpaI 
restriction proﬁ   les of IncF CTX-M-15 plasmids from Escherichia 
coli isolates in the Appendix Table. Cluster analysis was done by 
using Fingerprinting II in Informatix software version 3.0 (Bio-Rad 
Laboratories, Hercules, CA, USA) and applying the unweighted 
pair group method with arithmetic averages (optimization 0.5%, 
tolerance 1.00%). Ph, phylogenetic; ST, sequence type; RFLP, 
restriction fragment length polymorphism; Can, Canada; Fra, 
France; Por, Portugal; Swi, Switzerland; Ind, India; Kuw, Kuwait; 
Sp, Spain. Dissemination of Escherichia coli β-Lactamase CTX-M-15
In conclusion, worldwide dissemination of blaCTX-M-15 
is driven by B2 or D E. coli clones associated mainly with 
urinary tract infections or IncFII plasmids containing a 
multiple antimicrobial drug–resistance platform that con-
tributes to spread of CTX-M-15. Further studies to test 
the stability/variability and ﬁ  tness of particular plasmids 
among different bacterial hosts will be relevant in develop-
ing additional strategies to control dissemination of antimi-
crobial drug resistance.
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